drugset / Trial / NCT01123278

Testosterone Replacement in Metabolic Syndrome and Inflammation

NCT01123278

Phase 4 Completed 82 enrolled University of Roma La Sapienza
RandomizedCrossoverQuadruple-blindTreatment

Summary

Hypogonadism (HG) frequently complicates the Metabolic Syndrome (MetS), whether testosterone replacement (TRT) is beneficial has not been clearly ascertained. This study was designed to address the effects of TRT on insulin resistance, body composition and pro-inflammatory status in naïve patients with MetS and HG.

Timeline

Start
2004-01
Primary completion
2014-10
Completion
2014-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 50 mg Other